Talent Bridge
Awardees & Projects
“Data gaps that bottleneck aging biomarker discovery”
Marton Meszaros
-
This project addresses a critical bottleneck in aging research: the lack of robust, clinically viable biomarkers. By identifying key data gaps, outlining validation pathways, and proposing targeted datasets, it aims to shift the field from academic curiosity to actionable progress.
The ideal outcome is a new standard for aging biomarker development, one that enables faster drug development, attracts focused investment, and meets regulatory requirements. By catalyzing collaboration between researchers, biotech, funders, and regulators, this work lays the groundwork for biomarkers that can actually be used in trials, in clinics, and in the real world.
In short: this project could change how we measure aging… and how quickly we can act on it.
-
The promise of aging biomarkers, and “aging clocks” has captured widespread interest, yet their impact on clinical practice and drug development remains limited. This piece argues that a major bottleneck in creating truly useful aging biomarkers lies in the quality and structure of the human datasets used for their discovery and validation.
For biomarkers to be clinically meaningful, they must be robust, predictive of health outcomes, responsive to interventions, and practical for use in trials. Most current efforts fall short because they rely on datasets that are either too small, lack longitudinal data, or don't include key variables like environmental exposures, functional outcomes, or repeated sampling. Moreover, the discovery of biomarkers is often divorced from the rigorous validation processes needed to ensure real-world utility.
To break this bottleneck, three key projects are proposed:
Proposal A: Build a high-quality longitudinal discovery dataset with repeated sampling and deep phenotyping.
Proposal B: Create robustness datasets to test how potential biomarkers behave under various confounding conditions (e.g., time-of-day, illness, recent meals).
Proposal C: Re-contact participants from existing cohorts to expand sampling and improve metadata.
These projects aim to complement current large biobanks and enable the next generation of aging biomarkers, ones that can meaningfully accelerate drug development, support regulatory approval, and eventually inform clinical care. The path forward will require thoughtful dataset design, rigorous validation, and collaboration across sectors.
-
Marton is driven by the belief that aging and the diseases it causes is the greatest source of human suffering and the most impactful target for scientific intervention. Hailing from Hungary, Marton left his hometown at the ripe age of 13 to pursue his education. With a background as a Medical Doctor and spanning diagnostic development for early-stage Alzheimer’s and aging-focused drug discovery, Marton is uniquely positioned to tackle what he sees as the biggest bottleneck in the field: the lack of high-quality human data needed to define, measure, and ultimately intervene in biological aging.
His work focuses on designing and building the next generation of longitudinal biobanks optimized for biomarker development and translational drug research. Through the Talent Bridge project, Marton is exploring what data is actually required for clinically useful aging biomarker development work that aligns directly with his current efforts but would not be feasible to pursue as deeply without public support.
Marton ultimately aims to help build the foundational infrastructure that will enable meaningful, real-world progress in slowing and preventing human aging through his future ventures.
“Advancing Longevity Trials:
Lessons from mTOR-Targeting Interventions”
Nicolas Di Leo
-
mTORC1 inhibition is one of the few longevity strategies with a deep mechanistic foundation, decades of human trials, and repeated signals across aging-relevant domains. Yet translating this pathway into therapies that meaningfully improve healthspan has been difficult. This project aims to reduce “avoidable failure” in mTORC1-based aging trials by extracting practical lessons from the full spectrum of human evidence: exploratory academic studies, industry-led programs, and the newest wave of trials. The intended impact is simple and concrete: better trial designs (indication, dosing, endpoints, monitoring) that can survive regulatory scrutiny, produce interpretable outcomes, and accelerate real-world deployment of geroprotective therapies.
-
This piece is an informal systematic review of mTOR-targeting clinical trials conducted with longevity-oriented intent, organized around chronic disease contexts that serve as realistic entry points for “treating aging by treating age-related disease.” It synthesizes published trial outcomes and design choices, contrasts academic and biotech development strategies, and integrates insights from interviews with teams leading ongoing trials, including multiple Impetus-funded projects within the Norn Group network. The review focuses on how specific design variables—population enrichment, dose and schedule, primary endpoint construction, and target-engagement biomarker strategy—determine whether a trial produces actionable evidence or yields ambiguous signals that are difficult to translate. The final section consolidates the major gaps, unresolved questions, and practical opportunities, with concrete recommendations for improving the next generation of mTORC1-focused geroscience trials.
-
Nicolas is an early-career researcher focused on preclinical and clinical strategies to target aging. He earned his bachelor’s degree in Italy while completing his thesis work at the University of Copenhagen, then began his master’s training at the Karolinska Institute in Stockholm and carried out his thesis research at the University of Cambridge, maintaining a consistent focus on basic metabolic research. Motivated by the scientific challenge and broad relevance of the aging process, he decided to dedicate his career to longevity research. Nicolas Di Leo is currently a PhD student in the Developmental and Cell Biology program at Charles University and conducts research between Prague, Cambridge (MA), and Massachusetts General Hospital. In David Sabatini’s lab, he works on drug discovery efforts targeting components of the mTORC1 pathway, with the long-term goal of translating these insights into clinically testable interventions and ultimately building a biotech company.
Fund the next talent bridge project
Support our mission by contributing a donation.
Make sure to select “Talent Bridge” under ‘Select a Program to Support:’
Norn Group, Inc. is a tax-exempt nonprofit under Section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law.